ATOS
ATOS mini TA with fib linesNot surprised that we fell hard after breaking the uptrend (green line) at $8, retested the line at $8.40 to perfection and then fell about 35% to current prices.
What surprises me more is that the $5.66 support didn't hold and is now acting as a resistance zone. If we do break this mini resistance, I have no doubt that we will test the $6.60 fib region again.
Else, I can see this stock trading between the $4.10 and $5.66 region for a few days/weeks. If it does go lower and hold the 4.10 support I'm a buyer again. Good luck to all holders, I'm sure we all know the potential of this company.
SHORT | ATOS | H&S PatternNASDAQ:ATOS
This is not a temporary pattern and I expect weeks or months of decline before any fundamental news release.
Possible Scenario: SHORT
Evidence : Bearish price action, Head and Shoulder Pattern
TP1: 4.50 TO 4.60 as buy zone
TP2: 3.20 TO 3.30 as buy zone, strong support, most of the HF accumulated at this range for 2 weeks.
It's in distribution phase of stock life-cycle
Distribution Phase
The distribution phase begins as the markup phase ends and price enters another range period. The shares are being sold over a period of time—the opposite of accumulation. This time, the sellers want to maintain higher prices until the shares are sold.
Whether it is distribution or accumulation is less easy to discern at this point. It is more important to be prepared for the next signal, rather than trying to predict the next move.
One of the most common distribution patterns is known as the head-and-shoulders pattern. Rounding or a dome shape indicates distribution preceding the markdown stage.
Source: Investopedia (www.investopedia.com)
* This is my idea and could be wrong 100%.
🟢NEW POSITION $ATOS Target 8.00 for 29.03%$ATOS Target 8.00 for 29.03%
Or double position at 4.40
—
On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average.
I start every position with 1% of my account and build from there as needed and as possible.
I am not your financial advisor. Watch my setups first before you jump in… My trade set ups work very well and they are for my personal reference and if you decide to trade them you do so at your own risk. I will gladly answer questions to the best of my knowledge but ultimately the risk is on you. I will update targets as needed.
GL and happy trading.
I finally added my YouTube Training Video to my profile tagline since I’m not allowed to on here. It’s a quick 15 minute training video on how to set up your chart and how to spot opportunities. So check here first but If you have questions just message me.
SHORT | ATOS | Temporary price action | Valid before JulyNASDAQ:ATOS
LONG TERM I'm 100% Bullish, this is a possibility for 1 week
Possible Scenario: SHORT
Evidence: Price action
I expect a healthy correction, just temporary, before 28th June. and then it will bounce up to 12+ before July 16.
* It's my idea and could be wrong 100%
Long | ATOSNASDAQ:ATOS
It looks bullish to me, we have a gap above 5.80,
Possible Scenario: Long
Evidence: Price Action, smart money activities, Solid Fundamentals and Russel 2000 Inclusion
Call options, Strike 12$, 07/16/21
Call options, Strike 9$, 07/16/21
TP1 : 6.10
TP2: 7.30
TP3: 9.5
TP4: 18
*This is my idea and could be wrong 100%
Here We Go (Again?) With ATOSThis is familiar territory with ATOS . Not only is there a very clear and significant support level on the chart, there's also a multi-year level of resistance the ATOS is sitting at right now. The biggest question is Now What?
" Earlier this month, Atossa revealed data from a Phase 2 Endoxifen study in breast cancer. It met primary and secondary endpoints. The Phase 2 study was conducted on behalf of Atossa by Avance Clinical, a leading Australian CRO. Based on the results, the company also discussed its plan to apply to the FDA for approval to begin a clinical study in the US 'as soon as possible.' With meaningful results and potential for more clinical trials in the US, ATOS could be on the list of biotech penny stocks on Robinhood to watch this summer ."
Quote Source: 7 Penny Stocks On Robinhood To Watch In June 2021
ATOS BIG BUY/LONG POTENTIAL 2.65 to 140.00 By Mid 2022!ICKER CODE: ATOS
Company Name: ATOSSA THERAPEUTICS, INC
Industry: US Stocks Health Technology Medical Specialties
Position Proposed: BUY
FOMO BUY ENTRY: NOW READY (4.00-5.20)
NEXT BUY ENTRY: (2,65 - 3.35)
1st Partial Take Profit: 140.00 (Mid 2022)
2nd Partial Take Profit: 200.00 (Mid 2024)
3RD Partial Take Profit: 320.00 (2027)
1st PARTIAL SHORT TERM TP: 30:200
2nd PARTIAL SHORT TERM TP: 140.00
Stop Loss: 3.00
Technical Analysis
1. FALLING WEDGE PATTERN (COMPLETED )
2. HEAD & SHOULDERS PATTERN (PARTIALLY COMPLETE)
2. Area of Confluence on EMA & structure level
4. Fibonacci Retracement at 0.618 OR 0.786
5. Safest Take Profit will land 80 % equivalent to the length of head and neckline
level 2 of Fibonacci Expansion Blue Zone
ATOS - Dump or Buy? 🤷-Atossa Therapeutics Inc (ATOS) stock is trading at $4.76 as of 10:00 AM on Friday, Jun 4, a rise of $0.32, or 7.09% from the previous closing price of $4.44. The stock has traded between $4.55 and $4.92 so far today. Volume today is light. So far 2,739,675 shares have traded compared to average volume of 13,614,422 shares.
-Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in the US. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
-Prognosticator Edward Woo lifted said price target on Atossa to an even $8 per share from the previous $7.75. The new level is slightly more than twice the most recent closing price of the clinical-stage biotech. Almost needless to say, Woo has a buy rating on the stock; this remained unchanged with the price target raise.
-Atossa's most promising pipeline drug is Endoxifen, an oral treatment for breast cancer. Recently, it has also been developing a pair of medications for COVID-19. Since breast cancer is a particularly devastating and relatively widespread ailment, the company has great upside potential if Endoxifen tests well.
-Woo has been very bullish on Atossa from the get-go. He initiated coverage on the stock with a buy recommendation last September. Slapping a $7 per-share price target on it at the time, he wrote that "this valuation appropriately balances out the company's high risks with the company's high growth prospects and large upside opportunities."
$ATOS Target 4.09 for 29.43% $ATOS Target 4.09 for 29.43%
Or next add level is at 2.23
Support at the MA of RSI... let's go towards target 🙌🏼
—
On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average.
I start every position with 1% of my account and build from there as needed and as possible.
I am not your financial advisor. Watch my setups first before you jump in… My trade set ups work very well and they are for my personal reference and if you decide to trade them you do so at your own risk. I will gladly answer questions to the best of my knowledge but ultimately the risk is on you. I will update targets as needed.
GL and happy trading.